 |
5 Diseases |  |
67 Trials |
|
67 Trials |  |
4266 News |  |
| «12...52535455565758596061626364» |
- ||||||| zicronapine (Lu31-130) / Lundbeck
Trial completion: Safety and Efficacy of Zicronapine in Patients With Schizophrenia (clinicaltrials.gov) - Oct 29, 2012
P3, N=160, Completed, Sponsor: H. Lundbeck A/S
Active, not recruiting --> Completed
- aripiprazole / Generic mfg., risperidone / Generic mfg., olanzapine / Generic mfg.
Trial completion, Adverse events: Side Effects of Newer Antipsychotics in Older Adults (clinicaltrials.gov) - Oct 16, 2012
P4, N=406, Completed, Sponsor: Veterans Medical Research Foundation
Active, not recruiting --> Completed Recruiting --> Completed
- | risperidone / Generic mfg.
New P1 trial: A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers (clinicaltrials.gov) - Oct 15, 2012
P1, N=24, Completed, Sponsor: Hoffmann-La Roche
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Risperdal Consta (risperidone depot formulation) / J&J
Clinical: Switching From Consta® to Sustenna® in Patients With Schizophrenia (clinicaltrials.gov) - Sep 30, 2012
P=N/A, N=50, Recruiting, Sponsor: Seoul National University Hospital
- | pomaglumetad methionil (DB103) / Denovo
Trial termination: A Long-Term, Open-Label, Study on Schizophrenia (clinicaltrials.gov) - Sep 27, 2012
P2/3, N=1210, Terminated, Sponsor: Eli Lilly and Company
Recruiting --> Completed Recruiting --> Terminated; The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.
- Serlect (sertindole) / Lundbeck, Abbott
Trial termination: The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=14, Terminated, Sponsor: University of Zurich
Recruiting --> Terminated; The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population. Active, not recruiting --> Terminated; Not enough subjects have been recruited in the expected period.
- Serlect (sertindole) / Lundbeck, Abbott
Enrollment change: The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=14, Terminated, Sponsor: University of Zurich
Active, not recruiting --> Terminated; Not enough subjects have been recruited in the expected period. N=60 --> 14
- | risperidone / Generic mfg., paliperidone extended release / Generic mfg.
New P4 trial: A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia (clinicaltrials.gov) - Aug 19, 2012
P4, N=50, Recruiting, Sponsor: Johnson & Johnson Taiwan Ltd
- || risperidone / Generic mfg.
New P3 trial: A randomized double-blind, placebo-controlled study of risperidone in the treatment of aggressive antisocial behavior in youth. (EUDRACT) - Aug 16, 2012
P3, N=264, Ongoing, Sponsor: Radboud University Medical Centre Nijmegen
- metformin / Generic mfg., risperidone / Generic mfg.
Trial withdrawal: Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea (clinicaltrials.gov) - Jul 30, 2012
P=N/A, N=0, Withdrawn, Sponsor: Central South University
N=60 --> 14 Recruiting --> Withdrawn
- metformin / Generic mfg., risperidone / Generic mfg.
Enrollment change: Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea (clinicaltrials.gov) - Jul 30, 2012
P=N/A, N=0, Withdrawn, Sponsor: Central South University
Recruiting --> Withdrawn N=30 --> 0
- | clozapine / Generic mfg.
New P4 trial: CLOCS: Clozapine for Cannabis Use in Schizophrenia (clinicaltrials.gov) - Jul 11, 2012
P4, N=132, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
New P2/3 trial: Long-Term Study of MP-214 in Patients With Schizophrenia (clinicaltrials.gov) - Jun 21, 2012
P2/3, N=240, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
New P2/3 trial: A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia (clinicaltrials.gov) - Jun 20, 2012
P2/3, N=120, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- ||| New P3 trial: A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder (clinicaltrials.gov) - Jun 19, 2012
P3, N=39, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
New P2/3 trial: Safety and Efficacy of MP-214 in Patients With Schizophrenia (clinicaltrials.gov) - Jun 18, 2012
P2/3, N=480, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- ||||| risperidone / Generic mfg., iloperidone / Generic mfg.
New P2 trial: Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia (clinicaltrials.gov) - Jun 18, 2012
P2, N=260, Completed, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial initiation date: Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia (clinicaltrials.gov) - Jun 13, 2012
P4, N=50, Not yet recruiting, Sponsor: University of California, Los Angeles
N=30 --> 0 Initiation date: Oct 2011 --> Aug 2012
- | New P1 trial: Bioequivalence Study of Risperidone Tablet 1 mg Under Fed Condition (clinicaltrials.gov) - Jun 11, 2012
P1, N=48, Completed, Sponsor: IPCA Laboratories Ltd.
- ||||||| lurasidone / Generic mfg.
Trial completion: Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia (clinicaltrials.gov) - Jun 10, 2012
P3, N=440, Completed, Sponsor: Dainippon Sumitomo Pharma
Initiation date: Oct 2011 --> Aug 2012 Recruiting --> Completed
- ||| Vabicaserin (PF-05208769) / Pfizer
Enrollment change: Study Evaluating Vabicaserin in Subjects With Schizophrenia (clinicaltrials.gov) - Jun 6, 2012
P2, N=199, Completed, Sponsor: Pfizer
Recruiting --> Completed N=450 --> 199
- Trial withdrawal, Combination therapy: Anti-psychotic Medication (Stable Dose) Weight Loss Study (clinicaltrials.gov) - May 30, 2012
P2, N=0, Withdrawn, Sponsor: Avera McKennan Hospital & University Health Center
N=450 --> 199 Not yet recruiting --> Withdrawn
- Trial withdrawal, Combination therapy: Anti-psychotic Medication (New Use) Weight Loss Study (clinicaltrials.gov) - May 30, 2012
P2, N=0, Withdrawn, Sponsor: Avera McKennan Hospital & University Health Center
Not yet recruiting --> Withdrawn Not yet recruiting --> Withdrawn
- Trial initiation date, Combination therapy: Anti-psychotic Medication (New Use) Weight Loss Study (clinicaltrials.gov) - May 30, 2012
P2, N=0, Withdrawn, Sponsor: Avera McKennan Hospital & University Health Center
Not yet recruiting --> Withdrawn Initiation date: Apr 2012 --> Apr 2013
- Enrollment change, Combination therapy: Anti-psychotic Medication (Stable Dose) Weight Loss Study (clinicaltrials.gov) - May 30, 2012
P2, N=0, Withdrawn, Sponsor: Avera McKennan Hospital & University Health Center
Initiation date: Apr 2012 --> Apr 2013 N=80 --> 0
- Enrollment change, Combination therapy: Anti-psychotic Medication (New Use) Weight Loss Study (clinicaltrials.gov) - May 30, 2012
P2, N=0, Withdrawn, Sponsor: Avera McKennan Hospital & University Health Center
N=80 --> 0 N=30 --> 0
- |||| risperidone / Generic mfg.
Trial completion: InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics (clinicaltrials.gov) - May 30, 2012
P4, N=1085, Completed, Sponsor: Janssen-Cilag International NV
N=30 --> 0 Active, not recruiting --> Completed
- |||| pomaglumetad methionil (DB103) / Denovo
Trial completion: A Study in Schizophrenia Patients (clinicaltrials.gov) - May 29, 2012
P2, N=880, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P1 trial: A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics (clinicaltrials.gov) - May 28, 2012
P1, N=31, Completed, Sponsor: Janssen Research & Development, LLC
- | paliperidone extended release / Generic mfg.
New P4 trial: A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug (clinicaltrials.gov) - May 3, 2012
P4, N=13, Completed, Sponsor: Janssen Korea, Ltd., Korea
- ||| Korlym (mifepristone) / Corcept Therap
Enrollment change: A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers (clinicaltrials.gov) - Apr 30, 2012
P2, N=76, Completed, Sponsor: Corcept Therapeutics
Active, not recruiting --> Completed N=100 --> 76
- Risperdal Consta (risperidone depot formulation) / J&J
Trial termination: Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation (clinicaltrials.gov) - Apr 22, 2012
P4, N=6, Terminated, Sponsor: David C. Henderson, MD
N=100 --> 76 Recruiting --> Terminated; The sponsor withdrew support due to slow accrual of eligible subjects.
- Risperdal Consta (risperidone depot formulation) / J&J
Enrollment change: Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation (clinicaltrials.gov) - Apr 22, 2012
P4, N=6, Terminated, Sponsor: David C. Henderson, MD
Recruiting --> Terminated; The sponsor withdrew support due to slow accrual of eligible subjects. N=72 --> 6
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Biomarker, Trial termination: Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia (clinicaltrials.gov) - Apr 19, 2012
P4, N=21, Terminated, Sponsor: Kettering Health Network
N=72 --> 6 Completed --> Terminated; Study terminated due to failure to meet sufficient enrollment for valid analysis
- Enrollment change: IMPACT: Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (clinicaltrials.gov) - Apr 19, 2012
P4, N=132, Recruiting, Sponsor: Johns Hopkins University
Completed --> Terminated; Study terminated due to failure to meet sufficient enrollment for valid analysis N=240 --> 132
- |||| PF-02545920 / Pfizer
Trial completion: An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia (clinicaltrials.gov) - Apr 8, 2012
P2, N=259, Completed, Sponsor: Pfizer
N=240 --> 132 Recruiting --> Completed
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Biomarker, Enrollment change: Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia (clinicaltrials.gov) - Apr 3, 2012
P4, N=21, Terminated, Sponsor: Kettering Health Network
Recruiting --> Completed N=125 --> 21
- |||| risperidone / Generic mfg.
Enrollment open: POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia (clinicaltrials.gov) - Mar 26, 2012
P2, N=60, Recruiting, Sponsor: PharmaNeuroBoost N.V.
N=125 --> 21 Not yet recruiting --> Recruiting
- risperidone / Generic mfg.
Biomarker, Enrollment change: CYP2D6 Pharmacogenetics in Risperidone-Treated Children (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=47, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Not yet recruiting --> Recruiting N=60 --> 47
- risperidone / Generic mfg.
Biomarker, Trial completion: CYP2D6 Pharmacogenetics in Risperidone-Treated Children (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=47, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
N=60 --> 47 Enrolling by invitation --> Completed
- Enrollment change: SMEAC: Metabolic Effects of Antipsychotic Substitution in Children (clinicaltrials.gov) - Mar 7, 2012
P2/3, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Enrolling by invitation --> Completed N=312 --> 0
- | risperidone / Generic mfg.
Enrollment open, MRI: Repetitive Transcranial Magnetic Stimulation for First-episode Schizophrenia Patients (clinicaltrials.gov) - Feb 12, 2012
P3, N=60, Recruiting, Sponsor: Xijing Hospital
N=312 --> 0 Not yet recruiting --> Recruiting
- ||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Trial completion: Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia (clinicaltrials.gov) - Feb 6, 2012
P1, N=129, Completed, Sponsor: Forest Laboratories
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| risperidone / Generic mfg., blonanserin / Generic mfg.
New P3 trial: Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone (clinicaltrials.gov) - Jan 22, 2012
P3, N=267, Completed, Sponsor: Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
- ||| pomaglumetad methionil (DB103) / Denovo
New P3 trial: A Long-Term Study in Schizophrenia (EUDRACT) - Dec 26, 2011
P3, N=14, Ongoing, Sponsor: Eli Lilly and Company`Lilly S.A.
- ||||| Caplyta (lumateperone) - Intra / Cellular Therapies
New P2 trial: Study of a Novel Antipsychotic ITI-007 in Schizophrenia (clinicaltrials.gov) - Dec 22, 2011
P2, N=335, Completed, Sponsor: Intra-Cellular Therapies, Inc.
- risperidone / Generic mfg., paliperidone extended release / Generic mfg.
Trial completion: Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia (clinicaltrials.gov) - Dec 21, 2011
P4, N=58, Completed, Sponsor: Chonnam National University Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- risperidone / Generic mfg., desipramine / Generic mfg.
Trial initiation date: RADIAUS: Risperidone and Desipramine in Alcohol Use and Schizophrenia (clinicaltrials.gov) - Dec 8, 2011
P2, N=40, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Recruiting --> Completed Initiation date: Aug 2011 --> Dec 2011
- risperidone / Generic mfg., desipramine / Generic mfg.
Enrollment open: RADIAUS: Risperidone and Desipramine in Alcohol Use and Schizophrenia (clinicaltrials.gov) - Dec 8, 2011
P2, N=40, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Initiation date: Aug 2011 --> Dec 2011 Not yet recruiting --> Recruiting
- ||||||| risperidone / Generic mfg.
Trial completion: Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy (clinicaltrials.gov) - Dec 4, 2011
P3, N=630, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed